While estrogens are mitogenic in breast cancer cells, the presence of estrogen receptor ␣ (ER␣) clinically indicates a favorable prognosis in breast carcinoma. To improve our understanding of ER␣ action in breast cancer, we used an original in vitro method, which combines transient transfection and Matrigel invasion assays to examine its effects on cell invasiveness. ER␣ expression in MDA-MB-231 breast cancer cells reduced their invasiveness by 3-fold in the absence of hormone and by 7-fold in its presence. Integrity of hormone and DNAbinding domains and activating function 2 were required for estradiol-induced inhibition, suggesting that transcriptional activation of estrogen target genes was involved. In contrast, these domains were dispensable for hormone-independent inhibition. Analysis of deletion mutants of ER␣ indicated that amino acids 179-215, containing the N-terminal zinc finger of the DNA-binding domain, were required for ligand-independent receptor action. Among different members of the nuclear receptor family, only unliganded ER␣ and ER␤ reduced invasion. Calreticulin, a Ca 2؉ -binding protein that could interact with amino acids 206-211 of ER␣, reversed hormone-independent ER␣ inhibition of invasion. However, since calreticulin alone also inhibited invasion, we propose that this protein probably prevents ER␣ interaction with another unidentified invasion-regulating factor. The inhibitor role of the unliganded ER was also suggested in three ER␣-positive cell lines, where ER␣ content was inversely correlated with cell migration. We conclude that ER␣ protects against cancer invasion in its unliganded form, probably by protein-protein interactions with the N-terminal zinc finger region, and after hormone binding by activation of specific gene transcription. (Molecular Endocrinology 14: 999-1009, 2000)
INTRODUCTION
Estrogen receptor ␣ (ER␣) is a ligand-inducible transcription factor that belongs to the superfamily of nuclear receptors (reviewed in Refs. 1 and 2). The more recently isolated ER␤ isoform has structural similarities to ER␣, but a different tissue distribution (3, 4) . Estrogen signal transduction involved highaffinity binding to ERs, conformational changes of ERs and recruitment of transcriptional auxiliary factors, binding to estrogen response elements (EREs) in gene promoters, and regulation of transcriptional activity in conjunction with other transcription factors bound to their cognate sites in the promoter. Molecular analysis has shown that ER␣, like other nuclear receptors, consists of separable domains responsible for DNA binding [DNA-binding domain (DBD), hormone binding domain (HBD)], and transcriptional activation. The N-terminal activation function (AF-1) of the purified receptor is constitutively active, whereas the activation function located within the C-terminal part (AF-2) requires hormone for its activity. In addition to this well known activation of target promoters containing EREs, other liganded ER actions involving recruitment of ER␣ to gene promoters lacking EREs via protein-protein interactions with promoter-bound transcription factors (5-9), or activation of the mitogen-activated protein kinase pathway (10) , have been proposed.
Estrogens and their receptors are implicated in the etiology of breast cancer (reviewed in Ref. 11) . In large clinical studies, ER␣ has been associated with a more favorable prognostic outcome in breast cancer patients (12) . While the mitogenic action of estrogens in breast cancer cells is well established (13) , several studies have correlated ER␣ expression to lower Matrigel invasiveness and reduced metastatic potential of breast cancer cell lines (14, 15) . This paradox suggests that ER expression could be associated with or involved in pathways that hinder cancer progression. A working hypothesis is that ER␣ protects against invasion of the basement membrane, an important step of the metastatic process required for cancer dissemination. Estrogen effects on cell invasiveness have been studied in vitro using Matrigel, a reconstituted basement membrane as host. Initial studies indicated that invasiveness of MCF7 breast cancer cells was increased by estradiol and also, paradoxically, by antiestrogens (16, 17) . More recent studies have confirmed the stimulatory effect of antiestrogens, such as 4-OHtamoxifen and ICI 164,384 but not the estradiolinduced stimulation (15, (18) (19) (20) (21) (22) . By contrast, estradiol appeared to significantly reduce invasiveness, and this inhibition was reversed by antiestrogens. This conclusion was noted in several ER␣-positive cancer cell lines established from breast (15) or ovary (20) , and in different ER␣-negative cancer cells constitutively expressing ER␣ after stable transfection (18, 19, 22) . Similar results were also obtained on the migration of normal cells from vascular smooth muscle (21) .
In the present study, after deletion of different ER domains, we demonstrate that ER␣, expressed in ER-negative MDA-MB-231 breast cancer cells, prevents invasion in vitro via two distinct mechanisms, according to its unliganded or liganded status. Estrogen-induced inhibition requires ER␣ domains normally involved in the transcriptional activation of ERE-containing promoters. In contrast, the unliganded receptor action appears to depend on a discrete ER␣ region that includes the N-terminal zinc finger of DBD and probably involves proteinprotein interaction.
RESULTS

Regulation of Invasiveness of Breast Cancer Cells by Unliganded ER␣ and Estrogen/Antiestrogen Treatment
The effect of ER␣ on invasiveness was assayed using a new method based on transient cotransfection of the ER␣-expression vector (HEGO), or the empty pSG1 vector, with the pGL3 vector constitutively expressing luciferase and used as a marker to assess only transfected cells, as described in Materials and Methods. The percentage of luciferase-positive cells migrating through Matrigel was compared in HEGO-transfected or control pSG1-transfected cells. The validity and reproducibility of this cotransfection method have been demonstrated in the highly invasive ER␣-negative MDA-MB-231 cell line (23) . As shown in Fig. 1A , estradiol or antiestrogen treatments did not significantly affect invasion of control pSG1-transfected cells. ER␣ expression induced a 3.3-fold decrease in the invasiveness of transfected cells in a ligand-independent manner. Estradiol treatment reinforced this effect by an additional 2-fold reduction in invasiveness. Among antiestrogens, the partial agonist/antagonist OH-tamoxifen did not significantly affect invasion whereas the pure antiestrogen ICI 164,384 almost totally reversed the strong inhibition due to the unliganded ER␣. In the presence of estradiol, both antiestrogens reversed the hormone action, but ICI 164,384 also reversed the effect due to the unliganded receptor. Immunofluorescence analysis after transient HEGO transfection revealed that treatment by 100 nM ICI 164,384 decreased the number of ER-positive nuclei by 6-fold as compared with control or estradiol-treated cells (data not shown). This indicated that reversal of the unliganded receptor effect by ICI 164,384 was probably due to this drastic decrease in receptor content.
We used the same assay in the absence of Matrigel to analyze the effect of ER␣ on one component of the invasion process, i.e. cell motility (Fig. 1B) . In the absence of ligand, ER␣ expression reduced cell motility to 69% of the control value, indicating that decreased invasion (30% of control) could be partly due to a motility effect.
Different ER␣ Domains Are Implicated in the Inhibition of Invasion Mediated by Unliganded and Hormone-Activated Receptors
To determine the ER␣ domains involved in the two inhibitions obtained in the absence and presence of estradiol, ER␣ deletion constructs were transfected in MDA-MB-231 cells, and their effects on cell invasion were compared (Fig. 2) . The expression and nuclear localization of all mutated proteins were also verified by immunofluorescence as described in Materials and Methods. In most experiments, transfection efficiency reached about 6 Ϯ 2% of total cells (data not shown). In the absence of ligand, the G400V-mutated ER␣ (HEO, 46% of pSG1) was slightly less inhibitory than the native ER␣ (HEGO, 29% of pSG1). Mutant HE15 (1-282) lacking the hormone binding domain and AF-2 function or HE91 containing two amino acid changes in the DBD (E203G, A207V), which prevented transactivation via an ERE (24) , was as effective as the wild-type ER␣, indicating that these functions are not involved in ligand-independent inhibition. Inversely, mutants HE19 (179-595) and HE11 (⌬185-251) truncated in A/B and C domains, respectively, were ineffective, suggesting that these domains are important. On the other hand, E 2 -induced inhibition was totally abolished when mutants deleted in the HBD (HE15) or in the DBD (HE11) or mutated in the ERE binding domain (HE91) or in the core region of AF2 (HEmutAF2) were transfected (Fig. 2) . In contrast, deletion of the A/B region (HE19) did not influence the hormonal effect.
Taken together, these data indicated that inhibition due to unliganded ER␣ and to the E 2 -activated receptor required different receptor domains. The hormone action required ERE binding and AF2, two functions classically involved in transcriptional activation of target genes. In contrast, these functions were dispensable for the unliganded receptor action, which appeared to be due only to its 1-282 amino-terminal region.
Inhibition of Invasiveness by Unliganded ER Involved the First Zinc Finger of the C Region
To further specify which part of the 1-282 amino acid region is involved in unliganded receptor action, A/B deletion mutants were analyzed. Deletions of any different part of the A/B region did not influence the inhibitory effect of the unliganded receptor (Fig. 3A) . Moreover, a point mutation of serine 118, previously described as essential for steroid-independent receptor activation (25, 26) , to a nonphosphorylatable alanine (HE457 or HE15/457) did not alter ER␣ and ER␣1-282 (HE15) efficiencies for inhibiting invasion (data not shown). The finding that the ER100 (⌬3-178) mutant was active while HE19 (⌬1-178) was inefficient indicated that the two N-terminal amino acids are required (Fig. 3A) .
Since these results excluded involvement of a specific A/B subregion, we then constructed mutants deleted in the C and D regions. The SV40 large T antigen nuclear localization signal (NLS) was added at the C terminus of HE15 to maintain nuclear targeting of mu- tants deleted in the three nuclear localization sequences in the 256-303 region of ER␣ (Fig. 3B ). Analysis of mutants ER106, ER107, and ER108 progressively deleted from amino acids 281 to 216 indicated that the D region and the second zinc finger of the C region are not necessary for inhibition. Taken together, these data indicated that the 3-178 (Fig. 3A) and 216-281 (Fig. 3B ) regions were dispensable for the inhibitory effect, and that the 179-215 first (or N-terminal) zinc finger region was essential. Finally, this was demonstrated using mutant ER103 (⌬150-215) derived from HE384 by additional deletion of this region, which was totally inactive. The relevance of the 179-215 region in the inhibitory effect of the unliganded receptor was also demonstrated using a short receptor mutant (ER110) containing only amino acids 1 and 2 and 178-215 of the receptor followed by NLS and a hemagglutinin epitope to detect its expression. This minimal sequence significantly reduced invasion to 52 Ϯ 14% of control. Immunofluorescence analysis demonstrated that the marked differences in the efficiency of these mutants were a direct consequence of the mutations and not due to differences in protein expression (Fig. 3C ). These data clearly identify an ER␣ region between amino acids 179 and 215, containing the first zinc finger, which is essential for inhibition of cell invasiveness in the absence of hormone.
The reversibility of the inhibitory effect of unliganded ER by ICI 164,384 was tested using receptor mutants either mutated in the ERE binding region (HE91) or deleted in HBD (HE15 and ER108). As shown in Fig. 4 , the effect of ICI 164,384 was not impaired when the ERE binding domain was mutated. By contrast, deletion of E/F domains totally prevented antiestrogen action. These data strongly suggest that ICI 164,384 inhibits receptor action after binding to the HBD, but independently of ERE-mediated transcription.
Unliganded Receptor Action Is Specific to ER␣ and ER␤: Analysis of Common Amino Acids
Since the DBD is well conserved within the nuclear receptor superfamily, we analyzed the effects of several receptors on MDA-MB-231 cell invasiveness in steroid-deprived culture conditions. As shown in Fig.  5A , receptors specific to androgens or glucocorticoids were totally ineffective on invasion in the absence of hormone. Among the estrogen/thyroid/retinoic acid receptor subfamily, the thyroid hormone receptor ␣1 (TR␣1), vitamin D receptor (VDR), and retinoid acid receptor ␣ (RAR␣) were also inactive. Invasion was specifically decreased 3-fold and 2-fold by the expression of ER␣ or ER␤, respectively. The lower efficiency of the ER␤ could be due to its endogenous presence in these cells, as previously suggested by mRNA studies (27) . These data indicated that inhibition of invasiveness in the absence of hormone was ER␣-and ER␤-specific and pointed to amino acids common to these receptors. The 179-215 amino-acid sequence of ER␣ was compared with the corresponding regions of the other receptors tested (TR␣1, VDR, and RAR␣) (Fig. 5B) . ER␣ showed higher homology with ER␤ than with any other receptor in this region. Seven amino acids (A186, Y191, W200, S201, A207, K210, G215) were found to be common to only ER␣ and ER␤ and might be essential for the action of the unliganded ER.
To further characterize the active region, we used two mutants, i.e. HE 73 and HE74 derived from HEO, each containing six amino acid changes from the ER sequence to the GR sequence (Fig. 6) . The HE73 plasmid containing mutations of four critical amino acids (A186, Y191, W200, and S201) common to only ER␣ and ER␤ inhibited invasion as efficiently as the wildtype receptor. By contrast, the HE74 plasmid mutated at six positions (203, 204, 207, 212, 213, 214) including only the ER common A207 had no significant effect on invasion (88 Ϯ 11%) even by transfecting a 3-fold higher plasmid concentration (data not shown). This inactivation confirms the importance of the whole 203-215 region but is not only dependent upon mutation of the common A207 since this amino acid was also mutated in the active mutant HE91 (see Fig. 2 ).
Modulation of the Hormone-Independent Antiinvasive Effect of ER by Calreticulin Expression
Calreticulin, a Ca 2ϩ -binding protein, is known to bind integrins at the cell surface and to modulate gene (28) and contains an ER-specific alanine that is essential for ERE binding specificity (29) . Calreticulin thus appears as a potential ER-interacting protein possibly involved in hormone-independent ER-induced inhibition of invasion. When calreticulin was coexpressed with HE15 by transient transfection in MDA-MB-231 cells, the inhibitory effect of this HBD-deleted mutant was totally repressed, and invasion was unaltered as compared with control cells (Fig. 7) . These data confirmed the implication of the first zinc finger domain in the antiinvasive effect. However, when tested alone, calreticulin expression reduced Matrigel invasion to 31%, i.e. as efficiently as ER␣ expression. Similar inhibition was observed after transfection of 1-10 g of calreticulin expression vector (data not shown). It is not surprising that calreticulin was a negative modulator of invasion since this protein is known to increase integrin-mediated cell adhesion and spreading (28) . Taken together, these data indicate that calreticulin prevents the hormone-independent inhibition of invasion by ER␣, probably through interaction with its first zinc finger region, and suggests that calreticulin prevents ER␣ interaction with another unknown nuclear factor that activates invasion.
Inverse Correlation between ER␣ Expression and Cell Motility in ER-Positive Cell Lines
ER-positive breast cancer cell lines are less invasive in vitro and less metastatic in vivo than their ER-negative counterparts (14, 15) . In all breast cancer cell lines studied by immunocytochemistry, we observed heterogeneous expression of ER␣, with a wide range of intense to negative nuclear staining (Fig. 8A) . We used this heterogeneity to test whether the ER␣ content in individual cells was correlated with their motility capacities. A motility test was used instead of the invasion test because of the low invasiveness of ER␣-positive cell lines and the low seeding cell density required for immunostaining of individual cells. The percentage of immunostained cells was determined in the upper and lower side of the filter containing nonmigrating and migrating cells, respectively (Fig. 8A) . The percentage of ER␣-positive cells was lower in the migrating cell population than in the nonmigrating one. This difference was significant in three different cell Vectors expressing ER␣ (HEO) or mutant receptors HE73 or HE74, each containing six mutations (underlined amino acids) in the 179-215 region, were transfected in MDA-MB-231 cells and their effects on cell invasiveness were determined as described in Fig. 3 . Arrows indicate amino acids common to ER␣ and ER␤ but not to other receptors (see Fig.  5B ).
lines, MCF7, ZR75.1, and T47D (Fig. 8B) . In control experiments, we verified that this decrease in ER␣ positivity was not due to differences in cell densities between the two sides of the filter by immunostaining of serial dilutions of MCF7 cells (data not shown).
The fact that unliganded ER␣ expression was correlated with decreased motility of the three breast cancer cell lines was consistent with direct evidence obtained by transfection of ER␣-negative cells. Taken together, these in vitro data indicated a protective role of ER␣ against invasion by breast cancer cells.
DISCUSSION
Several studies indicated that estrogen decreased in vitro invasiveness and motility of breast (15, 18, 22) and ovarian (20) cancer cells. In addition, evidence of estrogen-induced inhibition of cancer aggressiveness was obtained in an experimental murine metastasis model using ER␣-expressing MDA-MB-231 cells (18) . Moreover, epidemiological studies of breast cancer risk in women using hormone replacement therapy (HRT) are in accordance with a decrease of tumor invasion mediated by estrogen (30) . Among women using HRT (80% received preparations containing estrogen alone), the risk of breast cancer increased, but these tumors were stage 1 with more favorable prognosis. Compared with tumors in never-users, those in HRT-users are less invasive to axillary lymph nodes and to distant sites. These data suggest that, in addition to their initial promoter role in breast cancer, estrogens could prevent spreading of cancer cells.
In this study, we used an original method that combines transient gene expression with Matrigel invasion assay to specify the receptor domains involved in estradiol inhibition of invasion. The estradiol effect is probably due to the classical activation of target gene transcription since it required ERE binding and AF2 domain integrity, two transactivation prerequisites. This strongly suggests that some estrogen-regulated genes negatively controlled invasion. Among estrogen-regulated proteins, those increasing cell-cell adhesion, such as E-cadherin, or decreasing matrix degradation, such as ␣1-antichymotrypsin are possible candidates (reviewed in Ref. 31) .
The major finding of this study is the strong inhibitory effect of unliganded ER␣ on cancer cell invasion. In previous experiments using stable transfection, analysis of two transfectants was not sufficient to render a conclusive decision on the inhibitory effect of unliganded ER␣ on invasion (18) . Possible artefacts related to the cell cloning procedure were eliminated by this new transient transfection approach. We could reproducibly inhibit cell invasion by full-length ER␣ expression in the absence of hormone. Evidence that ER␣ acted through an E 2 -independent mechanism was demonstrated by the action of different mutants lacking the hormone binding domain. Moreover, the strong inhibitory effect of the unliganded receptor was reversed by addition of the pure antiestrogen ICI 164,384 but not by the partial agonist/antagonist OHtamoxifen. We have also shown that ICI 164,384 activity requires the E/F region, but not ERE-mediated transcription, and is associated with a 6-fold decrease in the number of ER-stained nuclei. This suggests that ICI 164,384 prevents unliganded receptor action by ER degradation after its binding to the HBD. These data are in agreement with previous studies in native ER-positive cells showing that ER␣ stability was decreased in the presence of ICI 164,384 (32) but not in the presence of OH-tamoxifen (33) .
Using ER␣ mutants, we demonstrated that the 1-215 region (ER108) of the receptor was as efficient as the full-length receptor in the absence of ligand. Moreover, ERE-mediated transactivation and the A/B region containing the AF1 transactivation function were dispensable for this action. This contrasts with the previously proposed mechanism for steroid-independent activation of ER␣ requiring the functional A/B region, serine 118 phosphorylation, and ERE binding (25, 26) .
Analysis of mutants in the C and D regions revealed that deletion of the first zinc finger of the C region totally prevented ligand-independent inhibition, whereas other deletions flanking this zinc finger sequence were ineffective. Moreover, the minimal 178-215 sequence preceded by two terminal amino acids appeared sufficient to inhibit invasion. The active conformation of the critical 179-215 region is probably favored by the presence of a short (two or more amino acids) terminal sequence. As inhibition of invasion is restricted to the two ER isoforms among different members of the nuclear receptor superfamily, we identified seven amino acids common to only ER␣ and ER␤ by sequence comparison of the 179-215 region. However, the analysis of HE73 and HE74 mutants pointed out the importance of the 203-214 sequence rather than common amino acids located in the 186-207 region.
On the basis of these data, we propose that unliganded ER decreases invasiveness via interaction of the first zinc finger region with an unknown nuclear factor. The possibility that unliganded ER reversed invasion via a direct genomic effect due to DNA interaction was excluded by the activity of HE91, ER108, and ER110 mutants. Previous published data have shown that 1) mutations in HE91 prevented transactivation of ERE-mediated responses (24); and 2) deletions of the C-terminal zinc finger or of the 222-226 dimerization domain, as found in ER108 and ER110 mutants, abolished DNA binding of ER (34) and DBD dimerization (35) . Moreover, other examples of DBD regions that have a transcriptional role distinct from DNA binding have already been described (36, 37) .
Among the possible candidate proteins interacting with the DBD region of ER␣ (38-40), we tested calreticulin since this protein was known to specifically interact with the first zinc finger of different nuclear receptors (28, 40) . Calreticulin expression was able to reverse the inhibitory effect of HE15 but also inhibited invasion when tested alone. This indicates that calreticulin is not the ER␣ interacting factor that positively regulates invasion, but its interaction could prevent the binding of ER␣ to this unknown activator. The possibility that ER␣ could interfere with AP1-directed gene activity (6, 8, 9, 41) via a protein-protein interaction with the c-Jun protein (9) was excluded since the ER␣ region interacting with c-Jun is probably not the first zinc finger (Ref. 9 and C. Teyssier and D. Chalbos, unpublished data), and we showed that c-Jun overexpression did not influence the ER␣ effect on cell invasiveness (our unpublished data).
In mammary carcinogenesis, the promoting role and mitogenic effect of estrogens are well demonstrated, whereas the presence of ER␣ paradoxically seems to be associated with more differentiated and less invasive tumors. Moreover, large clinical studies have shown that ER␣ is a favorable prognostic marker in primary breast tumors. This was also confirmed in breast cancer cell lines in which ER␣ positivity was associated with low Matrigel invasiveness and low metastatic potential in mice. In this study, we present the following evidence that ER␣ per se could have a protective role against cancer progression: 1) Transient expression of the unliganded ER␣ and several mutants deleted in the hormone binding domain drastically reduced MDA-MB-231 cell invasiveness in Matrigel tests. 2) Studies in three ER␣-positive cell lines showed that in hormone-deprived conditions, the ER␣ content was inversely correlated with cell motility. These hormone-independent effects of ER␣ also suggest a function for ER variants deleted in exon 3 (second zinc finger) or exon 4 (part of HBD) that have been found to occur naturally in normal and neoplastic estrogen target tissues (42, 43) . In addition to the antitumor properties of the transfected ER␣ previously shown in the presence of estrogen (18, 44, 45) , the strong antiinvasive activity associated with expression of the unliganded receptor also suggests potential practical applications in cancer gene therapy.
We conclude that unliganded and hormone-activated ER␣ decrease in vitro cancer cell invasiveness via distinct mechanisms. This is evidence of a protective role of ER␣ in cancer progression and supports hormone-independent ER␣ function. This finding could help to explain the favorable prognosis associated with the presence of ER␣ in primary breast cancers and lead to new therapeutic applications.
MATERIALS AND METHODS
Plasmids
Plasmids derived from the pSG5 or pSG1 vector expressing full-length human ER␣ (HEGO) or mutated forms (HE series) of the receptor were generously donated by P. Chambon, and their constructions have been previously described (46, 47) except for HEmut-AF2 containing four mutations in the core activating domain of AF2 that prevent its action (Ref. 48 and V. Vivat and P. Chambon, unpublished). ER100 plasmid (⌬3-178), a derivative of the HE344/384 (⌬3-50 and ⌬150-178), was created by XhoI excision of amino acids 50 to 150. The ER103 expression vector (⌬150-216) was constructed by replacement of the HE384 XhoIXbaI fragment (amino acids 179 to 379) with a PCR-generated fragment containing residues 216-379 with a XhoI site preceding amino acid 216. The deletion mutants ER106, ER107, and ER108 were constructed as follows. The expression vector HE15-NLS was first constructed using two complementary oligonucleotides coding for the SV40 large T antigen NLS Pro-Lys-Lys-Lys-Arg-Lys-Val (49), which were inserted at the 3Ј-end of ER␣1-282 (HE15 coding sequence) between XhoI and AocI sites. These oligonucleotides contained a new KpnI site, in front of the NLS. Mutants ER106 (⌬270-281), ER107 (⌬251-281), and ER108 (⌬216-281) were constructed by replacement of the HE15-NLS NotI-XhoI fragment (amino acids 65 to 282) with PCR-generated fragments containing residues 65-269 (plasmid ER106), 65-250 (plasmid ER107), and 65-215 (plasmid ER108) in front of a new XhoI site. Mutant ER110 was constructed from ER108 by replacement of EcoRI fragment by PCR-generated fragments containing human influenza hemagglutinin tag sequence YPYDVPDYA between the NLS and stop codon. Other human receptor cDNAs corresponding to ER␤ (provided by S. Mosselman) vitamin D (VDR), thyroid hormone (TR␣1), retinoic acid (RAR␣), androgen (AR), and glucocorticoid (GR) receptors (provided by P. Chambon) were used in pSG5 expression vector. Calreticulin cDNA inserted in pcDNA3 expression vector (Invitrogen, San Diego, CA) was provided by M. Michalak.
Cell Culture and Transfection
Human breast cancer cell lines MDA-MB-231, MCF7, T47D, and ZR 75.1 were maintained in monolayer cultures in DMEM supplemented with 10% FCS and 50 g ml Ϫ1 gentamycin. In all experiments, steroids were withdrawn from cells by 6 days of culture in phenol red-free DMEM supplemented with 10% dextran-coated charcoal-treated FCS (FCS-DCC).
Transient transfections of MDA-MB-231 cells were performed using the calcium phosphate DNA coprecipitation method. Near confluent cells were cotransfected in a 75-cm 2 flask with 3.75 g of steroid receptor expression vector or pSG control vector and 33.75 g of pGL3 vector (Promega Corp., Madison WI) coding for luciferase. Cells were exposed to the precipitate for 8 h, washed three times with phenol red-free medium, and incubated for an additional 16 h in fresh medium before the invasion assay. 5 transfected cells was layered on a 24-well plate to determine the total luciferase activity. After 24 h, cells were rinsed and lysed for 30 min with 100 l (for migrating cells on the lower side of the filter) or 300 l (for cells plated on 24-well plate) of lysis buffer containing 10% glycerol and 1% Triton X100 (Promega Corp.). Luciferase activities were determined on 100 l samples by measuring the luminescence (15-sec integration time) in a LKB luminometer (LKB, Rockville, MD) after the injection of 100 l of luciferase assay reagent (Promega Corp.). The percentage of migrating cells is given by the ratio of luciferase activity of invasive cells to luciferase activity of total cells ϫ 100. Values are means of three independent experiments performed in triplicate. The interexperiment coefficient of variation determined from 30 values was 4%. The validity and reproducibility of the transfection/invasion technique was described in greater detail by Platet and Garcia (23) .
For chemotaxis studies, cells were seeded on the Transwell filter as described for the invasion assay, but in the absence of Matrigel.
Immunocytochemistry
ER␣ immunostaining was performed 24 h after transient transfection of vectors expressing full-length and mutated ER␣. Cells were fixed and permeabilized with 3.7% formaldehyde for 12 min, cold methanol for 4 min, and cold acetone for 2 min and then saturated with 2.5% goat serum in phosphate saline buffer containing 4% BSA overnight at 4 C. Immunostaining was performed using mouse monoclonal ER␣ antibodies directed against either the amino-terminal A/B region (50) (2.5 g ml Ϫ1 of 1D5 antibody, from DAKO Corp., Carpinteria, CA) or carboxy-terminal amino-acids 495-594 (1 g ml Ϫ1 C311 antibody, from Santa Cruz Biotechnology, Inc., Santa Cruz, CA), with goat antimouse rhodamineconjugated antibody (Immunotech, Marseille, France) as second antibody. For chemotaxis studies in ER-positive cell lines, ER␣ was detected by immunoperoxidase staining using 1D5 antibody, antimouse biotinylated antibody, and the Vectastain kit (Vector Laboratories, Inc., Burlingame CA). Calreticulin and hemagglutinin expression was detected by double immunofluorescence using C-17 goat antihuman calreticulin antibody from Santa Cruz Biotechnology, Inc., and mouse monoclonal antihemagglutinin antibody from Roche Molecular Biochemicals (Mannheim, Germany).
